Search results
QRG Capital Management Inc. Sells 34,932 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)
ETF DAILY NEWS· 1 day agoQRG Capital Management Inc. cut its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 9.8% during the 4th quarter, ...
Takeda Pharmaceuticals earnings: profits, EPS down over 50% in Q4 financial results | Invezz
Invezz· 6 days agoThe company described it in a press release as “a year of significant loss-of-exclusivity impact”, a...
Takeda stock down 1% as operating profit declines
Investing.com· 6 days agoTakeda Pharmaceutical Company Limited (NYSE: TAK ) has surpassed its management guidance for revenue and core earnings per share (EPS) in fiscal year...
Why Is AC Immune (ACIU) Stock Up 45% Today?
InvestorPlace· 2 days agoAC Immune (NASDAQ:ACIU) stock is heading higher on Monday alongside the clinical-stage biopharmaceutical company’s earnings report for the first quarter...
Japan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50%
Benzinga via Yahoo Finance· 6 days agoOn Thursday, Japan’s drugmaker Takeda Pharmaceutical Company Limited (NYSE:TAK) announced a...
Catalyst's New CEO Has Big Ideas For The Small Biotech
Investor's Business Daily· 5 days agoWe believe we have that capability, we have the infrastructure. We believe, beyond just the...
UN agency authorizes second vaccine against dengue amid outbreaks in the Americas
Dayton Daily News· 3 hours agoIn a statement on Wednesday, the U.N. health agency said it approved the dengue vaccine made by the...
...Alzheimer's-Focused AC Immune Stock Trading Higher On Monday...AC Immune (NASDAQ:ACIU), Takeda ...
Benzinga· 2 days agoMonday, Takeda Pharmaceutical Company Limited TAK and AC Immune SA ACIU announced an exclusive, worldwide option and license agreement for AC Immune’s active ...
AC Immunity Shares Soar on Exclusive License Deal with Takeda
Morningstar· 2 days agoBy Dean Seal Shares of AC Immunity surged after the company signed announced an agreement with Takeda Pharmaceutical for an exclusive option to license ...
Takeda shells out $100m to license AC Immune’s Phase II Alzheimer’s therapy
Pharmaceutical Technology via Yahoo Finance· 2 days agoThe study will enrol approximately 500 patients. The study’s primary endpoint evaluates the...